The Claim
In esophageal squamous cell carcinoma, a metabolic signature characterized by high creatine and low hexokinase 3 expression accurately identifies a high-risk patient subtype with poor prognosis, achieving diagnostic accuracy exceeding 90% in training and validation cohorts.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In esophageal squamous cell carcinoma, patients with high creatine and low hexokinase 3 levels are consistently identified as a high-risk subgroup with poor prognosis, and this combination correctly classifies over 90% of patients in tested groups.
See the scientific wording
In esophageal squamous cell carcinoma, the combination of high creatine and low hexokinase 3 (HK3) forms a metabolic signature that accurately identifies a high-risk patient subtype with poor prognosis, with a diagnostic accuracy of over 90% in training and validation cohorts.
When creatine builds up and hexokinase 3 is low in esophageal cancer cells, macrophages switch to a suppressive state that shuts down immune attack, allowing the tumor to grow unchecked and spread.
What the research says
1 studyScientists found that when esophageal cancer tumors have lots of creatine and very little HK3, it’s a clear sign the patient is at high risk — and this test correctly spotted those patients over 90% of the time in their study.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.